 SAN FRANCISCO, Dec. 21, 2020 PRNewswire -- Kindred Biosciences, Inc. NASDAQ: KIN, a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis... 